The following excerpt is from a May 10, 2010 article published by PR Newswire. To read the article in its entirety, please click here.
SHENZHEN, China, May 10 /PRNewswire-FirstCall/ – Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) announces that the company successfully acquired the first contract for its Freeze-dried Varicella Vaccine.
After the HTDS acquired Approval for its Freeze-dried MEVAC-vari in this Central American country (company’s first Varicella vaccine approval in Latin America), the company closed the first contract in Guatemala and expects to ship and deliver its vaccine in May.
A source close to the company stated, “We are thrilled to close our first deal in less than two months after the final ministry approval. We offer very competitive products for the developing countries, and this is a great start for us on a market that offers a vast field of opportunities. Varicella, or chickenpox, is generally a mild viral illness. However, approximately 1 in 50 cases chickenpox associates with complications such as pneumonia and encephalitis, both attributed a high mortality rate. These complications can be fully eliminated by a simple vaccination. HTDS continues to seek out new opportunities in this part of the world as we are able to deliver affordable products to the parts of the world where basic health care lags behind only due to funding.”…
Click here to read the rest of the article, or here to read more articles related to health & safety.
Comments are closed.